Spero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD Cowen

Spero Therapeutics (NASDAQ:SPRO)‘s stock had its “hold” rating reiterated by equities researchers at TD Cowen in a research note issued on Monday,Benzinga reports.

Several other research analysts have also weighed in on SPRO. HC Wainwright lowered their price target on Spero Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Spero Therapeutics in a research report on Friday.

Spero Therapeutics Stock Up 0.8 %

NASDAQ:SPRO opened at $1.19 on Monday. The firm has a market capitalization of $64.24 million, a price-to-earnings ratio of 17.00 and a beta of 0.63. Spero Therapeutics has a twelve month low of $1.01 and a twelve month high of $1.89. The stock’s 50 day moving average price is $1.29 and its two-hundred day moving average price is $1.36.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SPRO. Virtu Financial LLC acquired a new position in shares of Spero Therapeutics during the 1st quarter worth approximately $31,000. Renaissance Technologies LLC increased its holdings in shares of Spero Therapeutics by 14.2% during the 2nd quarter. Renaissance Technologies LLC now owns 975,952 shares of the company’s stock worth $1,269,000 after acquiring an additional 121,492 shares during the last quarter. Acadian Asset Management LLC increased its holdings in shares of Spero Therapeutics by 121.8% during the 1st quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after acquiring an additional 418,742 shares during the last quarter. Murchinson Ltd. increased its holdings in shares of Spero Therapeutics by 1.3% during the 1st quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after acquiring an additional 11,210 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Spero Therapeutics by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after acquiring an additional 9,675 shares during the last quarter. 25.60% of the stock is owned by institutional investors and hedge funds.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.